Arrowhead Pharmaceuticals (ARWR) Stock
Clinical stage biotech developing gene silencing liver drugs. Here's the price, business snapshot, and what's worth knowing about Arrowhead Pharmaceuticals in October 2026.
Arrowhead Pharmaceuticals (ARWR) is a clinical-stage biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. Using a proprietary delivery platform designed to silence specific genes, Arrowhead advances candidates aimed primarily at liver-related diseases and other conditions where gene knockdown may be therapeutic. The business model is R&D‑driven: value tends to be tied to clinical milestones, regulatory progress and partnerships rather than stable product revenue. Investors should note the binary nature of clinical outcomes, the time and capital typically required to bring experimental therapies to market, and the potential for significant share-price volatility around trial results and deal announcements. The company may partner or licence programmes to larger pharmaceutical groups to share development risk and access commercial expertise. This summary is for educational purposes only and not investment advice; individual suitability depends on personal circumstances and risk tolerance.
Arrowhead Pharmaceuticals (ARWR) Stock Forecast
Analyst price target, next 12 months
$77.81
+21.2% vs today's $64.19
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Arrowhead Pharmaceuticals have a consensus 12-month target of $77.81, above the current price of $64.19.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Arrowhead Pharmaceuticals' stock, with a target price of $77.81.
Financial Health
Arrowhead Pharmaceuticals is showing strong revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage pipeline
Progress in human trials can materially change valuation, so clinical read-outs are worth watching — though outcomes are binary and can be unpredictable.
RNAi platform focus
A platform approach can create multiple opportunities if delivery and safety perform well, but technical and regulatory hurdles remain.
Partnerships and deals
Collaborations with larger pharma can de‑risk development and provide milestones, yet deal terms and reliance on partners also shape future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
